FDA Introduces New Approval Process for Rare Disease Therapies

The 'plausible mechanism pathway' aims to streamline approval for individualized treatments for rare and ultra-rare diseases.

Feb. 23, 2026 at 10:09pm

Got story updates? Submit your updates here. ›

The FDA has introduced a new approval process called the 'plausible mechanism pathway' that will allow for the approval of targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra-rare diseases where randomized controlled trials are not feasible. The new framework is designed to help get these types of personalized treatments to patients more efficiently.

Why it matters

Rare and ultra-rare diseases affect millions of Americans, but treatments have historically been difficult to develop and approve due to the challenges of conducting large clinical trials with small patient populations. This new FDA pathway aims to address this issue by providing a more streamlined approval process for individualized therapies that show promise based on early evidence.

The details

The plausible mechanism pathway will allow the FDA to approve certain bespoke, personalized treatments by 'generating substantial evidence of effectiveness and safety' through a single well-controlled clinical investigation supported by confirmatory evidence. This is exemplified by the case of an infant in Philadelphia treated successfully with a gene editing therapy for the rare disease carbamoyl-phosphate synthase 1 deficiency (CPS1). Researchers were able to customize the treatment to the infant's specific genetic mutation, demonstrating the potential of this approach for other rare diseases.

  • The FDA announced the new plausible mechanism pathway on February 23, 2026.

The players

Robert F. Kennedy Jr.

The U.S. Secretary of Health and Human Services.

Martin Makary, MD, MPH

The Commissioner of the U.S. Food and Drug Administration.

Rebecca Ahrens-Nicklas, MD, PhD

The director of the Children's Hospital of Philadelphia (CHOP) Gene Therapy for Inherited Metabolic Disorders Program.

Kiran Musunuru, MD, PhD, MPH

A cardiologist, geneticist and gene editor at the University of Pennsylvania, and co-director of the Orphan Disease Center, a collaborative center between CHOP and Penn.

Got photos? Submit your photos here. ›

What they’re saying

“The beauty of this kind of therapy is that it has a small component that acts like a GPS. Switch the address in that GPS, and that therapy will go to another address and make the desired change.”

— Kiran Musunuru (Healio)

“Promising science too often stalls before it reaches patients. The biggest hurdle is moving from a first-in-human trial to regulatory approval. Getting across that gap is what allows treatments to become commercially available, reimbursed and scaled, so all patients who need them can access them, not just those in a single, small study.”

— Rebecca Ahrens-Nicklas, Director, CHOP Gene Therapy for Inherited Metabolic Disorders Program (Healio)

What’s next

The FDA will finalize the details of the new plausible mechanism pathway in the coming months, with the goal of implementing the framework to accelerate the development and approval of individualized therapies for rare and ultra-rare diseases.

The takeaway

This new FDA approval process represents a significant step forward in addressing the longstanding challenges of developing treatments for rare diseases, where small patient populations have historically made it difficult to conduct large clinical trials. By focusing on the underlying science and mechanism of action rather than requiring extensive clinical data, the plausible mechanism pathway has the potential to bring more personalized therapies to patients in need.